Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Inventory (2023 - 2025)

Telix Pharmaceuticals has reported Inventory over the past 3 years, most recently at $37.1 million for Q4 2025.

  • Quarterly Inventory rose 48.65% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 48.65% year-over-year, with the annual reading at $37.1 million for FY2025, 56.99% up from the prior year.
  • Inventory was $37.1 million for Q4 2025 at Telix Pharmaceuticals, up from $24.9 million in the prior quarter.
  • Over five years, Inventory peaked at $37.1 million in Q4 2025 and troughed at $11.3 million in Q4 2023.
  • The 3-year median for Inventory is $24.9 million (2024), against an average of $24.4 million.
  • Year-over-year, Inventory skyrocketed 121.36% in 2024 and then skyrocketed 48.65% in 2025.
  • A 3-year view of Inventory shows it stood at $11.3 million in 2023, then skyrocketed by 121.36% to $24.9 million in 2024, then surged by 48.65% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Inventory are $37.1 million (Q4 2025), $24.9 million (Q4 2024), and $11.3 million (Q4 2023).